Amgen
Non-profit generic drug company Civica Rx appoints former Amgen quality chief as new CEO
October 9, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbot, Amgen, Bayer, civica rx, generic drugs, hospitals
Civica Rx, a new not-for-profit generic drug company aimed at reducing the price of lifesaving medicines, has appointed former Amgen …
Rheos Medicines appoints Roche Senior Vice President and R&D head as new CEO
September 6, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, CEO, Roche, cembridge, massachussets, rheos, sanjay keswani
The Cambridge Massachusetts-based biopharmaceutical company Rheos Medicines has appointed former Roche Senior Vice President and Global R&D Head, Dr Sanjay …
CHMP recommend white blood cell growth stimulator biosimilar to EMA
July 30, 2018Sales and Marketing Amgen, CHMP, EMA, Neulasta, biosimilar, chemotherapy, pegfilgrastim
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of two separate …
Amgen announces resignation of two top executives
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Anthony C Cooper, R&D, biotech, retire, sean harper
Amgen’s head of R&D, Dr Sean Harper, has announced that he is retiring from his current position as Executive Vice …
Top Ten most popular articles on Pharmafile.com this week
July 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, China, GSK, Gilead, J&J, JJ, Pfizer, Remicade, Roche, antimicrobial resistance, biosimilar, pharma, pricing, viagra
With the UK in the grip of a record-breaking heatwave, it’s hard to focus on much else over here, but …
FDA approves Pfizer biosimilar version of Amgen’s Neupogen
July 23, 2018Sales and Marketing Amgen, FDA, Neupogen, Nivestym, Pfizer, pharma
The FDA has announced its decision to approve Pfizer’s Nivestym, the firm’s biosimilar version of Amgen’s Neupogen (filgrastim), for use …
Amgen biosimilar proves non-inferior to J&J’s Remicade in rheumatoid arthritis
June 27, 2018Research and Development, Sales and Marketing Amgen, Johnson & Jonson, Remicade, pharma, rheumatoid arthritis
Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it …
Mylan lands biosimilar sucker punch to Amgen’s blockbuster
June 6, 2018Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta
Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …
Amgen/Novartis migraine med gets CHMP nod
June 4, 2018Sales and Marketing Aimovig, Amgen, Novartis, biotech, drugs, pharma, pharmaceutical
Amgen and Novartis have announced that their newly FDA-approved treatment for migraines has received a recommendation from the CHMP, generally …
Amgen/Novartis potential blockbuster migraine med gets FDA nod
May 18, 2018Medical Communications, Sales and Marketing Allergan, Amgen, Novartis, biotech, drugs, migraine, pharma, pharmaceutical
The first in a new class of migraine treatments has just received approval from the FDA; Amgen and Novartis’ Aimovig …
Europe expands approved indication of Amgen’s Repatha in cardiovascular disease
May 17, 2018Sales and Marketing Amgen, Repatha, cardiovascular disease, pharma
Amgen has revealed that its PCSK9 inhibitor Repatha (evolocumab) has received approval from the European Commission in a new indication: …
Top Ten most popular articles on Pharmafile.com this week
April 20, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, EMA, GW Pharma, J&J, JJ, MHRA, Mylan, Novartis, Sanofi, Shire, Takeda, biotech, drugs, epipen, keytruda, pharma, pharmaceutical
It’s the end of another week and there’s really been one story that has dominated the headlines – Takeda’s potential …
Novartis snatches Amgen and BMS veteran for CMO and Drug Development Head
April 19, 2018Medical Communications Amgen, BMS, Bristol-Myers Squibb, Novartis, appointment, pharma
Dr John Tsai has been welcomed to the fold as Novartis’ new Head of Global Development and Chief Medical Officer, …
Amgen and Novartis’ Aimovig shines in migraine at Phase 3
April 18, 2018Research and Development Aimovig, Amgen, Novartis, migraine, pharma
Amgen has lifted the curtain on complete Phase 3 data for its calcitonin gene-related peptide receptor (CGRP) inhibitor Aimovig (erenumab) in …
Uncovering trends in the future of real world data
March 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, AstraZeneca, feature, pharma, real world data, real world evidence
A new report has canvassed the intentions of industry players in the use of real world data and evidence over …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
